- Home
- MCRI vs IMCR Comparison
MCRI vs IMCR Comparison
Compare MCRI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- IMCR
- Stock Information
- Founded
- MCRI 1972
- IMCR 2008
- Country
- MCRI United States
- IMCR United Kingdom
- Employees
- MCRI N/A
- IMCR N/A
- Industry
- MCRI Hotels/Resorts
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRI Consumer Discretionary
- IMCR Health Care
- Exchange
- MCRI Nasdaq
- IMCR Nasdaq
- Market Cap
- MCRI 1.9B
- IMCR 1.7B
- IPO Year
- MCRI 1993
- IMCR 2021
- Fundamental
- Price
- MCRI $103.70
- IMCR $34.21
- Analyst Decision
- MCRI Hold
- IMCR Buy
- Analyst Count
- MCRI 5
- IMCR 9
- Target Price
- MCRI $96.20
- IMCR $57.00
- AVG Volume (30 Days)
- MCRI 92.3K
- IMCR 286.9K
- Earning Date
- MCRI 10-22-2025
- IMCR 11-05-2025
- Dividend Yield
- MCRI 1.16%
- IMCR N/A
- EPS Growth
- MCRI N/A
- IMCR N/A
- EPS
- MCRI 4.22
- IMCR N/A
- Revenue
- MCRI $534,693,999.00
- IMCR $356,145,000.00
- Revenue This Year
- MCRI $6.87
- IMCR $29.67
- Revenue Next Year
- MCRI $4.19
- IMCR $11.12
- P/E Ratio
- MCRI $24.60
- IMCR N/A
- Revenue Growth
- MCRI 4.65
- IMCR 26.78
- 52 Week Low
- MCRI $69.99
- IMCR $23.15
- 52 Week High
- MCRI $113.88
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- MCRI 51.64
- IMCR 48.79
- Support Level
- MCRI $103.32
- IMCR $33.90
- Resistance Level
- MCRI $107.00
- IMCR $37.00
- Average True Range (ATR)
- MCRI 2.18
- IMCR 1.54
- MACD
- MCRI 0.07
- IMCR 0.04
- Stochastic Oscillator
- MCRI 51.47
- IMCR 39.35
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.